STAT16h
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Zacks.com on MSN16h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
Zacks.com on MSN21h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
STAT21h
CAR-T promising for autoimmune disease while perhaps preserving fertility
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in ...